natgillin/translations-raw huggingface dataset:
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Naxcel were greater than any risks when used as recommended.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Naxcel večje od z njim povezanih tveganj, kadar se uporablja po priporočilih.
What benefit has Naxcel shown during the studies?
Kakšne koristi je zdravilo Naxcel izkazalo med študijami?
The Committee therefore recommended that Naxcel should be given a marketing authorisation.
Odbor je zato priporočil odobritev dovoljenja za promet z zdravilom Naxcel.
Ceftiofur (like other cephalosporins or penicillins) may cause allergic reaction in humans or in animals, which may occasionally be serious.
Ceftiofur (kot drugi cefalosporini oziroma penicilini) lahko povzročijo alergijsko reakcijo pri ljudeh ali živalih, ki je lahko v določenih primerih huda.
In cattle, the withdrawal period in meat and offal is nine days, and in milk it is zero days.
Pri govedu je obdobje karence za meso in drobovino devet dni, za mleko pa nič dni.
What is the risk associated with Naxcel?
Kakšna tveganja so povezana z zdravilom Naxcel?
It is available as a suspension for injection into the muscle of the neck (for pigs) or under the skin at the base of the ear (for cattle).
Na voljo je kot suspenzija za injiciranje v vratno mišico (pri prašičih) in pod kožo pod ušesom (pri govedu).
In pigs, these infections can be respiratory tract infections such as lung infections, infections of the joints and infections affecting the general health of the pigs such as septicaemia (blood infection).
Pri prašičih so te okužbe lahko okužbe dihal, kot je okužba pljuč, okužbe sklepov in okužbe, ki vplivajo na splošno zdravje, kot je septikemija (okužba krvi).
Data from laboratory studies with different bacteria showed that ceftiofur is effective against bacteria involved in causing the pig and cattle diseases listed above.
Podatki iz laboratorijskih raziskav različnih bakterij kažejo, da je ceftiofur učinkovit proti bakterijam, ki pri prašičih in govedu povzročajo zgoraj navedene bolezni.
It should, therefore, not be used in animals that have previously shown an allergy to any cephalosporin or penicillin-type antibiotics.
Zato se ga ne sme uporabljati pri živalih z znano alergijo na kateri koli cefalosporin ali penicilinski antibiotik.
If any symptoms occur after accidental exposure to Naxcel, for example a skin rash, then the advice of a doctor should be sought immediately.
Če se po nenamerni izpostavitvi zdravilu Naxcel pojavijo kakršnikoli simptomi (na primer kožni izpuščaj), se nemudoma posvetujte z zdravnikom.
The most common side effects noted during the studies were local swelling and other mild reactions at the injection site (skin discoloration or small cysts).
Najpogostejši neželeni učinki v študijah so bile lokalne otekline in druge blage reakcije na mestu injiciranja (sprememba barve kože ali majhne ciste).
The benefit-risk balance may be found in the scientific discussion module of this EPAR.
Razmerje med koristmi in tveganji najdete v modulu o znanstveni razpravi tega evropskega javnega poročila o oceni zdravila (EPAR).
Naxcel should be handled with care and all of the recommended precautions be taken to avoid exposure to the product.
Z zdravilom Naxcel je treba ravnati previdno in upoštevati vse previdnostne ukrepe proti izpostavitvi zdravilu.
The efficacy of the treatment with Naxcel was compared with the results seen in another group of cattle that were treated with ceftiofur hydrochloride.
Učinkovitost zdravljenja z zdravilom Naxcel je bila primerjana z rezultati, opaženimi pri drugi skupini goveda, ki je bila zdravljena s ceftiofur kloridom.
All these cephalosporin antibiotics, including ceftiofur, kill bacteria by disrupting the building of the bacterial cell walls.
Cefalosporinski antibiotiki, vključno s ceftiofurjem, uničujejo bakterije s prekinitvijo nastajanja celične stene bakterije.
Naxcel is used to treat pigs and cattle that have an infection caused by certain groups of bacteria.
Zdravilo Naxcel se uporablja pri prašičih in govedu za zdravljenje okužb, ki so jih povzročile nekatere skupine bakterij.
Why has Naxcel been approved?
Zakaj je bilo zdravilo Naxcel odobreno?
Cephalosporin and penicillin antibiotics can cause allergies in humans, and sometimes these allergies can be very serious.
Cefalosporinski in penicilinski antibiotiki lahko povzročijo pri ljudeh alergije, ki so lahko v določenih primerih zelo hude.
Naxcel should therefore not be handled by anyone who is hypersensitive (allergic) to these antibiotics, or by anyone who has been advised not to work with them.
Z zdravilom Naxcel ne smejo rokovati osebe, ki so preobčutljive za (alergične na) te antibiotike, oziroma osebe, ki so jim odsvetovali delo z njimi.
Naxcel has been investigated in pigs with respiratory diseases caused by various bacteria or in pigs suffering from severe lameness, fever or other clinical signs of septicaemia, polyarthritis (inflammation of the joints) or polyserositis (inflammation of the internal body membranes) associated with Streptococcus suis infection.
Zdravilo Naxcel je bilo proučeno tudi pri prašičih z boleznimi dihal,ki so jih povzročile različne bakterije, ter pri prašičih, ki so imeli hudo šepavost, zvišano telesno temperaturo ali druge klinične znake septikemije, poliartritis (vnetje sklepov) oziroma poliserozitis (vnetje notranjih mren), povezan z okužbo s Streptococcus suis.
Naxcel is an antibiotic suspension that contains ceftiofur (as crystalline free acid) as the active substance.
Zdravilo Naxcel je antibiotična suspenzija, ki vsebuje ceftiofur (kristalinična prosta kislina) kot zdravilno učinkovino.
However, these withdrawal periods in cattle are only valid when Naxcel has been injected under the skin in nonedible tissue at the recommended location (the base of the ear).
Navedena obdobja karence pri govedu veljajo le, če je bilo zdravilo Naxcel injicirano pod kožo v neužitno tkivo na priporočenem mestu (pod ušesom).
In these trials, Naxcel was either used on its own or compared with another authorised antibiotic (amoxicillin) or with placebo (a dummy treatment without any active substance).
V teh preskušanjih so uporabili samo zdravilo Naxcel ali pa so ga primerjali z drugim odobrenim antibiotikom (amoksicilinom) ali s placebom (zdravilom brez vsake zdravilne učinkovine).
In cattle, Naxcel is used to treat foot rot (an infection of the feet) and acute puerperal metritis (an infection of the womb occurring after calving) in cases where treatment with another antimicrobial has failed.
Pri govedu se zdravilo Naxcel uporablja pri gnitju nog (okužba nog) in akutnega puerperalnega metritisa (okužba maternice po telitvi), kadar zdravljenja z drugimi antimikrobnimi zdravili niso bila uspešna.
What is Naxcel used for?
Za kaj se zdravilo Naxcel uporablja?
The active substance in Naxcel is ceftiofur, which belongs to a class of antibiotics called “third generation cephalosporins”.
Zdravilna učinkovina zdravila Naxcel je ceftiofur, ki je antibiotik iz skupine „cefalosporinov tretje generacije“.
How has Naxcel been studied?
Kako je bilo zdravilo Naxcel raziskano?
How does Naxcel work?
Kako zdravilo Naxcel deluje?
What is Naxcel?
Kaj je zdravilo Naxcel?
In cattle, Naxcel was given under the skin at the base of the ear.
Pri govedu se zdravilo Naxcel daje kot injekcija pod kožo pod ušesom.
Zentiva (listed in section 6).
Zentiva (navedeno v poglavju 6).
The marketing authorisation holder shall submit PSUR for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.
Imetnik dovoljenja za promet z zdravilom mora PSUR za to zdravilo predložiti v skladu z zahtevami, določenimi v seznamu referenčnih datumov Unije (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES in objavljenem na evropskem spletnem portal o zdravilih.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 20 April 2007
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum prve pridobitve dovoljenja za promet z zdravilom: 20 April 2007
A final analysis was performed with an actual median follow-up of 96 months.
Končna analiza je bila opravljena, ko je dejansko mediano spremljanje doseglo 96 mesecev.
Date of last renewal: 20 April 2012
Datum zadnjega podaljšanja dovoljenja za promet: 20 April 2012
• decrease of the sodium and/or magnesium in your blood (electrolyte balance disorders)
• znižanje natrija in/ali magnezija v krvi (motnje ravnotežja elektrolitov)
The performance status scale, for head and neck (PSS-HN) subscales designed to measure understandability of speech, ability to eat in public, and normalcy of diet, was significantly in favour of TPF as compared to PF.
Lestvica stanja zmogljivosti s podlestvicama za glavo in vrat (PSS-HN), namenjenima merjenju razumljivosti govora, sposobnosti uživanja hrane na javnem mestu in normalnosti hrane , je signifikantno govorila v korist TPF v primerjavi s PF.
The safety and efficacy of Docetaxel Zentiva in nasopharyngeal carcinoma in children aged 1 month to less than 18 years have not yet been established.
Varnost in učinkovitost zdravila Docetaxel Zentiva za zdravljenje nazofaringealnega karcinoma pri otrocih od 1 meseca do manj kot 18 let starosti nista ugotovljeni.
Secondary end-points included change of pain, global rating of quality of life by EuroQoL-5D, Lung Cancer Symptom Scale, and changes in Karnofsky performance status.
Sekundarne končne točke so vključevale spremembe bolečin, celotno oceno kakovosti življenja z EuroQoL-5D, Lung Cancer Symptom Scale in spremembe zmogljivostnega stanja po Karnofskem.
Given the fact that docetaxel every week presented a slightly better safety profile than docetaxel every 3 weeks, it is possible that certain patients may benefit from docetaxel every week.
Glede na to, da je docetaksel tedensko pokazal nekoliko boljši profil varnosti kot zdravilo Docetaxel Zentiva vsake tri tedne, je možno, da bi določenim bolnikom koristil docetaxel tedensko.
Your doctor may change the dose and frequency of dosing depending on your blood tests, your general condition and your response to Docetaxel Zentiva.
Zdravnik bo morda spremenil odmerek in pogostnost odmerjanja glede na izvide vaših preiskav krvi, vaše splošno stanje in vaš odziv na zdravilo Docetaxel Zentiva.
SPECIAL STORAGE CONDITIONS Do not store above 25°C.
POSEBNA NAVODILA ZA SHRANJEVANJE Ne shranjujte pri temperaturi nad 25°C.
Older people patients treated with TCF should be closely monitored.
Starejše bolnike, ki dobivajo TCF, je treba natančno nadzirati.
Docetaxel Zentiva will be given by infusion into one of your veins (intravenous use).
Zdravilo Docetaxel Zentiva boste dobili v infuziji v eno od ven (intravenska uporaba).
1000 mg/m2 per day for 5 days.
1000 mg/m2/dan od 1. do 4. dneva.
For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer (see section 5.1).
Pri bolnicah z operabilnim rakom dojke z negativnimi bezgavkami mora biti adjuvantno zdravljenje omejeno na bolnice, primerne za prejemanje kemoterapije v skladu z mednarodno sprejetimi merili za primarno zdravljenje zgodnjega raka dojke (glejte poglavje 5.1).
The adverse reactions considered to be possibly or probably related to the administration of docetaxel have been obtained in:
Podatki o neželenih učinkih, ki so morda ali verjetno povezani z uporabo docetaxela , so bili zbrani pri:
Between infusions of Docetaxel Zentiva the following may occur, and the frequency may vary with the combinations of medicines that are received:
Med infuzijami zdravila Docetaxel Zentiva se lahko pojavi naslednje in pogostnost se lahko razlikuje glede na kombinacijo zdravil, ki so uporabljena:
For docetaxel/carboplatin combination, neither equivalent nor non-inferior efficacy could be proven compared to the reference treatment combination VCis.
Za kombinacijo docetaksel Zentiva /karboplatin v primerjavi z referenčno terapevtsko kombinacijo VCis ni bilo mogoče dokazati niti enakovredne niti neinferiorne učinkovitosti.
This is because Docetaxel Zentiva or the other medicine may not work as well as expected and you may be more likely to get a side effect.
Bodisi zdravilo Docetaxel Zentiva bodisi drugo zdravilo namreč mogoče ne bo delovalo tako dobro, kot bi bilo pričakovati, in verjetneje je, da se bo pri vas pojavil kakšen neželen učinek.
Docetaxel Zentiva was administered as a 1-hour infusion, all other medicinal products were given intravenously on day 1 every three weeks.
Zdravilo Docetaxel Zentiva je bilo uporabljeno v 1-urni infuziji, vsa druga zdravila pa intravensko 1. dan na tri tedne.
MARKETING AUTHORISATION HOLDER Zentiva k.s., U kabelovny 130, 102 37 Prague 10, Czech Republic
IMETNIK DOVOLJENJA ZA PROMET Zentiva k.s., U kabelovny 130, 102 37 Prague 10, Češka
Pharmacotherapeutic group: Taxanes, ATC Code: L01CD02
Farmakoterapevtska skupina:taksani, oznaka ATC: L01CD02
Docetaxel Zentiva will be administered to you by a healthcare professional.
Zdravilo Docetaxel Zentiva vam bo dal pristojni zdravstveni delavec.
Before each treatment with Docetaxel Zentiva, you will have blood tests to check that you have enough blood cells and sufficient liver function to receive Docetaxel Zentiva.
Pred vsako uporabo zdravila Docetaxel Zentiva boste opravili preiskave krvi za ugotovitev, ali imate dovolj krvnih celic in zadostno delovanje jeter, da lahko dobite zdravilo Docetaxel Zentiva.
Docetaxel is a lipophilic substance but it is not known whether it is excreted in human milk.
Docetaxel je lipofilna snov, vendar ni znano , ali se izloča v materino mleko.
95% CI p-valuea* a Time to event variables: Stratified log-rank test.
Vrednost pa* a Spremenljivke časa do dogodka: stratificirani log-rang test.
Exploratory subgroup analyses for disease-free survival for patients who meet the 2009 St. Gallen chemotherapy criteria - (ITT population) were performed and presented here below:
Opravljene so bile eksplorativne analize podskupin glede preživetja brez bolezni pri bolnicah, ki izpolnjujejo St.-Gallenska merila 2009 za kemoterapijo (populacija ZNZ); predstavljene so spodaj:
If the vials are stored under refrigeration, allow the required number of boxes of Docetaxel Zentiva concentrate for solution for infusion to stand below 25°C for 5 minutes before use.
Če so viale shranjene v hladilniku, pustite potrebno število škatel koncentrata za raztopino za infundiranje zdravila Docetaxel Zentiva pred uporabo 5 minut stati na temperaturi do 25°C.
This regimen was administered every three weeks for 4 cycles in case at least a minor response (≥ 25% reduction in bidimensionally measured tumour size) was observed after 2 cycles.
To terapevtsko shemo so uporabljali vsake tri tedne za 4 cikle, če so po 2 ciklih opazili vsaj manjši odziv ( ≥ 25 % zmanjšanje dvodimenzionalno merjene velikosti tumorja).
The incidence of serious adverse events was higher in the older people compared to younger patients.
Incidenca resnih neželenih učinkov je bila pri starejših bolnikih večja kot pri mlajših.
Docetaxel1 n = 94
docetaksel 1 n = 94
Docetaxel Zentiva must NOT be administered if you are pregnant unless clearly indicated by your doctor.
Zdravila Docetaxel Zentiva NE smete dobiti, če ste noseči, razen če vam vaš zdravnik ne odredi drugače.
Discuss with your doctor if you suffer from alcohol dependency, epilepsy or liver impairment.
Posvetujte se z zdravnikom, če ste odvisni od alkohola, imate epilepsijo ali okvaro jeter.
The most commonly reported adverse reactions of Docetaxel Zentiva alone are: decrease in the number of red blood cells or white blood cells, alopecia, nausea, vomiting, sores in the mouth, diarrhoea and tiredness.
Najpogosteje poročani neželeni učinki zdravila Docetaxel Zentiva samega so: zmanjšanje števila rdečih ali belih krvnih celic, alopecija, slabost, bruhanje, razjede v ustih, driska in utrujenost.
What Docetaxel Zentiva is and what it is used for
Kaj je zdravilo Docetaxel Zentiva in za kaj ga uporabljamo
If the concomitant use of a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) cannot be avoided, a close clinical surveillance is warranted and a dose-adjustment of docetaxel may be suitable during the treatment with the strong CYP3A4 inhibitor (see section 4.4).
Če se sočasni uporabi močnega zaviralca CYP3A4 (npr. ketokonazola, itrakonazola, klaritromicina, indinavirja, nefazodona, nelfinavirja, ritonavirja, sakvinavirja, telitromicina in vorikonazola) ni mogoče izogniti, je potreben natančen klinični nadzor in med zdravljenjem z močnim zaviralcem CYP3A4 je lahko primerna prilagoditev odmerka docetaksela (glejte poglavje 4.4).
METHOD AND ROUTE(S) OF ADMINISTRATION Ready to add to infusion solution.
POSTOPEK IN POT(I) UPORABE ZDRAVILA Pripravljeno za dodatek raztopini za infundiranje.
Docetaxel Zentiva contains alcohol.
Zdravilo Docetaxel Zentiva vsebuje alkohol.
Symptomatic cardiac failure was reported in 2.2% of the patients who received docetaxel plus trastuzumab compared to 0% of patients given docetaxel alone.
O simptomatskem srčnem popuščanju so poročali pri 2,2 % bolnikov, ki so dobivali docetaxel in trastuzumab, in pri 0 % bolnikov, ki so dobivali samo docetaxel.
Docetaxel every 3 weeks
Končna točka docetaxel vsake 3 tedne docetaxel vsak teden
• 1276 patients (744 and 532 in TAX 316 and GEICAM 9805 respectively) who received docetaxel in combination with doxorubicin and cyclophosphamide (clinically important treatment related adverse events are presented).
• 1276 bolnikih (744 v TAX 316 in 532 GEICAM 9805), ki so prejemali docetaksel v kombinaciji z doksorubicinom in ciklofosfamidom (predstavljeni so klinično pomembni z zdravljenjem povezani neželeni učinki).
Prophylactic G-CSF may be used to mitigate the risk of haematological toxicities.
Za zmanjšanje nevarnosti hematološke toksičnosti se lahko uporablja profilaktično G-CSF.
You must not be given Docetaxel Zentiva:
Zdravila Docetaxel Zentiva ne smete dobiti:
Docetaxel Zentiva has been prescribed by your doctor for the treatment of breast cancer, special forms of lung cancer (non-small cell lung cancer), prostate cancer, gastric cancer or head and neck cancer: - For the treatment of advanced breast cancer, Docetaxel Zentiva could be administered either alone or in combination with doxorubicin, or trastuzumab, or capecitabine.
Zdravnik vam je zdravilo Docetaxel Zentiva predpisal za zdravljenje raka dojke, posebne vrste pljučnega raka (nedrobnocelični pljučni rak), raka prostate, raka želodca ali raka glave in vratu: - Za zdravljenje napredovalega raka dojke se lahko zdravilo Docetaxel Zentiva uporablja sam ali v kombinaciji z doksorubicinom ali trastuzumabom ali kapecitabinom.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tako kot vsa zdravila , ima lahko tudi to zdravilo neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Tel: +40 021 304 7597
Tel: +40 021 304 7597 PV
You must not become pregnant during treatment with this medicine and must use an effective method of contraception during therapy, because Docetaxel Zentiva may be harmful for the unborn baby.
Med zdravljenjem z zdravilom Docetaxel Zentiva ne smete zanositi in morate uporabljati učinkovito kontracepcijsko zaščito, ker zdravilo Docetaxel Zentiva lahko škoduje vašemu nerojenemu otroku.
The pharmacokinetic profile of cisplatin administered shortly after docetaxel infusion is similar to that observed with cisplatin alone.
Farmakokinetični profil cisplatina, uporabljenega kmalu po infuziji docetaxel, je podoben kot po uporabi samega cisplatina.
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
izdaja zdravila je le s posebnim režimom (glejte Prilogo I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
The median TTP was 37.3 weeks (95% CI: 33.4 - 42.1) in AT arm and 31.9 weeks (95% CI: 27.4 - 36.0) in AC arm.
Mediana časa do napredovanja je bila v kraku AT 37,3 tedna (95 % IZ: 33,4 - 42,1) in v kraku AC 31,9 tedna (95 % IZ: 27,4 - 36,0).
What Docetaxel Zentiva contains - The active substance is docetaxel (as trihydrate).
Kaj vsebuje zdravilo Docetaxel Zentiva - Zdravilna učinkovina je docetaksel (v obliki trihidrata).
See also section “Docetaxel Zentiva contains ethanol (alcohol)” below.
Glejte tudi poglavje »Zdravilo Docetaxel Zentiva vsebuje etanol (alkohol)«.
Marketing Authorisation Holder Zentiva k.s.
Imetnik dovoljenja za promet z zdravilom Zentiva k.s.
The European Medicines Agency has waived the obligation to submit the results of studies with Docetaxel Zentiva in all subsets of the paediatric population in breast cancer, non-small cell lung cancer, prostate cancer, gastric carcinoma and head and neck cancer, not including type II and III less differentiated nasopharyngeal carcinoma (see section 4.2 for information on paediatric use).
Evropska agencija za zdravila (EMA) je odstopila od obveze za predložitev rezultatov študij z zdravilom Docetaxel Zentiva za vse skupine pediatrične populacije za raka dojke, nedrobnoceličnega pljučnega raka, raka prostate, karcinom želodca in raka glave in vratu, ne vključujoč manj diferenciiran nazofaringealni karcinom tipa II oz. III (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
As with all parenteral products, Docetaxel Zentiva infusion solution should be visually inspected prior to use, solutions containing a precipitate should be discarded.
Tako kot vsa zdravila za parenteralno uporabo je treba tudi raztopino za infundiranje zdravila Docetaxel Zentiva pred uporabo pregledati; če vsebuje precipitat, jo je treba zavreči.
permanent hair loss has been observed
(pogostnost neznana) so opazili trajno izgubo las.
For combination with capecitabine, the most frequent treatment-related undesirable effects (≥ 5%) reported in a phase III study in breast cancer patients failing anthracycline treatment are presented (see capecitabine summary of product characteristics).
Pri kombinaciji s kapecitabinom so predstavljeni najpogostejši z zdravljenjem povezani neželeni učinki (≥ 5 %), o katerih so poročali v študiji III. faze pri bolnicah z rakom dojke z neuspelim zdravljenjem z antraciklini (prosimo, glejte povzetek glavnih značilnosti kapecitabina).
If you are a man being treated with Docetaxel Zentiva you are advised not to father a child during and up to 6 months after treatment and to seek advice on conservation of sperm prior to treatment because docetaxel may alter male fertility.
Če ste moški, ki se zdravi z zdravilom Docetaxel Zentiva je priporočljivo, da ne zaplodite otroka med zdravljenjem in v obdobju 6 mesecev po koncu zdravljenja ter da pred začetkom zdravljenja poiščete nasvet glede ohranitve sperme, ker docetaksel lahko prizadene moško plodnost.
In patients who were 75 years of age or older, when compared to younger patients, neutropenia, anemia, diarrhea, dyspnea and upper respiratory tract infection were reported with a greater incidence (at least 10% higher).
Bolniki, stari 75 let ali več, so imeli v primerjavi z mlajšimi bolniki večjo (vsaj 10 % večjo) pojavnost nevtropenije, anemije, driske, dispneje in okužb zgornjih dihal.
Each vial of concentrate contains 0.5 ml of ethanol anhydrous (395 mg).
Vsaka viala koncentrata vsebuje 0,5 ml brezvodnega etanola (395 mg).
What you need to know before you use Docetaxel Zentiva
Kaj morate vedeti, preden boste uporabili zdravilo Docetaxel Zentiva
Based on a population pharmacokinetic analysis, there are no special instructions for use in the older people.
Za uporabo pri starostnikih glede na analizo farmakokinetike na populaciji ni posebnih navodil.